Anhui Meilai Pharmaceutical Co., Ltd.

Taking Chinese healthy subjects as the test subjects, a self-cross-control experimental design was adopted to measure the time course of the blood concentration of pemafibrate in the plasma of healthy subjects after administration of the test preparation pemafibrate tablets. , estimate the corresponding pharmacokinetic parameters, and use Pemafibrate tablets (trade name: PARMODIA®, specification: 0.1 mg) produced by Xinghe Co., Ltd. with a license as a reference to evaluate the bioequivalence between preparations. And observe the safety of Pemafibrate tablets in Chinese healthy subjects.

Healthy Chinese subjects were used as the test subjects. A self-crossover design was used to determine the time course of acipimox concentration in plasma after administration of acipimox capsules licensed by Anhui Meilai Pharmaceutical Co., Ltd. and produced by Bengbu Fengyuan Tushan Pharmaceutical Co., Ltd., and to estimate the corresponding pharmacokinetic parameters. Acipimox capsules (trade name: Olbetam®, specification: 0.25g) licensed by Pfizer Limited and produced by Pharmacia Italia SpA were used as reference to evaluate the bioequivalence between the preparations and to observe the safety of acipimox capsules in healthy Chinese subjects.